Peter Marks

Peter Ashley Marks is currently Non-Executive Deputy Chairman at Noxopharm Ltd. since 2016, Chairman at Newburyport Partners Pty Ltd., Chairman at Iris Metals Ltd. since 2024, Independent Non-Executive Director at Alterity Therapeutics Ltd. since 2010, Non-Executive Director at Emefcy Ltd., Director at rivusTV, Non-Executive Director at Electriq Global Ltd., Non-Executive Director at Evergold Minerals Ltd. since 2022, and Principal at Halcyon Corporate Pty Ltd. Former roles include Chairman at Motopia Ltd., Executive Chairman at Vitasora Health Ltd. from 2006 to 2011, Non-Executive Director at Armadale Capital Plc from 2009 to 2016, Director at KPMG Corporate Finance (Australia) Pty Ltd. from 1998 to 2001, Director-Corporate Finance at BBY Ltd. in 1991, Director at Peregrine Corporate Ltd., Associate Director at Merrill Lynch (Australia) Pty Ltd. from 1985 to 1988, Director at Savcor Group Ltd. in 2015, Director at Momentum Funds Management Pty Ltd. from 1992 to 1994, Non-Executive Director at Emefcy Group Ltd., Non-Executive Director at Elsight Ltd. from 2020 to 2021, Non-Executive Director at Fluence Corp.
Ltd. from 2015 to 2020, and Non-Independent Non-Executive Director at Nyrada, Inc. from 2018 to 2022.
Education includes undergraduate and graduate degrees from Monash University and an MBA from the University of Edinburgh Business School.